Difference between revisions of "Carmustine"
From Dog
| Line 3: | Line 3: | ||
Carmustine, similar in activity to [[lomustine]], is a mustard gas-related β-chloro-nitrosourea alkylating agent which crosslinks DNA and prevents its replication. | Carmustine, similar in activity to [[lomustine]], is a mustard gas-related β-chloro-nitrosourea alkylating agent which crosslinks DNA and prevents its replication. | ||
| − | It is usually administered as an adjunct drug in combination with [[cisplatin]]<ref>Wright KC ''et al'' (1987) Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs. ''Chemotherapy'' '''33(6)''':437-444</ref>, [[vincristine]] and [[prednisolone]]. | + | It is usually administered as an adjunct drug in combination with [[cisplatin]]<ref>Wright KC ''et al'' (1987) Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs. ''Chemotherapy'' '''33(6)''':437-444</ref>, [[vincristine]] and [[prednisolone]]. A new formulation with carmustine made available as a lipid nanoemulsion has also shown benefit<ref>Lucas SR ''et al'' (2013) Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. ''Vet Comp Oncol'' [http://www.ncbi.nlm.nih.gov/pubmed/23615221 Apr 25]</ref>. |
Carmustine has also been compounded into a local, sustained-release injectable viscous gel for intralesional treatment of oral [[melanoma]]<ref>Kitchell BE ''et al'' (1994) Intralesional implant for treatment of primary oral malignant melanoma in dogs. ''J Am Vet Med Assoc'' '''204(2)''':229-236</ref>. | Carmustine has also been compounded into a local, sustained-release injectable viscous gel for intralesional treatment of oral [[melanoma]]<ref>Kitchell BE ''et al'' (1994) Intralesional implant for treatment of primary oral malignant melanoma in dogs. ''J Am Vet Med Assoc'' '''204(2)''':229-236</ref>. | ||
Latest revision as of 06:26, 29 April 2013
Carmustine is a chemotherapy drug used primarily as an adjunct in treatment of lymphoma.
Carmustine, similar in activity to lomustine, is a mustard gas-related β-chloro-nitrosourea alkylating agent which crosslinks DNA and prevents its replication.
It is usually administered as an adjunct drug in combination with cisplatin[1], vincristine and prednisolone. A new formulation with carmustine made available as a lipid nanoemulsion has also shown benefit[2].
Carmustine has also been compounded into a local, sustained-release injectable viscous gel for intralesional treatment of oral melanoma[3].
Marked neutropenia is frequently observed following administration of this drug[4].
References
- ↑ Wright KC et al (1987) Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs. Chemotherapy 33(6):437-444
- ↑ Lucas SR et al (2013) Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. Vet Comp Oncol Apr 25
- ↑ Kitchell BE et al (1994) Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 204(2):229-236
- ↑ Ricci Lucas SR et al (2004) Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma. J Am Anim Hosp Assoc 40(4):292-299
